Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune ...

The findings, published today in the New England Journal of Medicine, showed a 76.6% response rate and 55.3% complete remission rate in 127 evaluable patients.The median event-free survival (EFS ...

and acquired a worldwide license to Precision's Azercabtagene Zapreleucel (azer-cel), an investigational allogeneic or "off the shelf" CD19 CAR T cell therapy program for autoimmune diseases and ...

The firm’s experienced professionals help clients analyze financial alternatives, identify strategic and financial sources of capital, and structure and negotiate terms, which meet their objectives.